Drug Database · Clinicians

Metformin + Sitagliptin

Brands (153) Janumet, Velmetia, Sitaglo M- 50/1000…Show all
Janumet · Velmetia · Sitaglo M- 50/1000 · Sitaplus · Tiglipza Plus · Unomet · Xiglip M · Acantha Plus · Adivia Met · Altuxermet · Co-Zincretin 50/500 · Co-Zincretin XR 100/1000 · Exesit-M · Fliptin Max · Forglip · Gliforge · Glucodrop · Glyxera Met · Glyxera Met XR · Janumet XR · KoztaTM Plus · Liptimet · Metasit · Philsitz-M · S-Metprime · SIGLIP-Met · Silamet · Sitagard-M · Sitaglo - M 50/850 · Sitajack-M · Sitakem-M · Sitamet · Sitanav Plus · Sitazit-M · Treviamet · Vilantra Plus · Acantha Max · Adivia Met XR · Agmetria · Altodiab · Amaziptin-M 1000 · Amaziptin-M 500 · Ambetria-M · Ambetria-M 500 · Azentin · Co-Zincretin 50/1000 · Curasit · CuroVia · Deglucom · Diaglip Duo 500 · Duoglica Plus 50/ 500 · Empalin · Gleeflor · Gleefor · Glimefer · Glipcor · Glipgludin · Glipiformin 50/500 · Glipiformin 50/850 · Glipstar-1000 · Gliptina Plus · Glucadrop Plus · Glucentra · Glucomed · Glucomed Plus · Gluconav · Glucosita · Glusimet · Gluviance-M · Glycoppex · Glysicare · Glysiptin Plus · Indous · Instadip-M 100/1000 · Instadip-M/50/500 · Jantin-M · Javamet · Kozta Plus · Kozta Plus XR · Lupigliptin Plus · Maedgliptin · Mestis · Metaglipt · METAGLIPTIN · Metglipzin · Metglyn · Metromin Plus · Metromin Plus 50/1000 · Metromin Plus 50/850 · Metsaphtin - 50/500 · Metsaphtin - 50/850 · Metsiglob · Metsita · Neoglip · Novasit-M 50/1000 · Novasit-M 50/500 · OP-Sita Duo · Ponicor · Premiliptin Plus · Retaformin Plus · Retaglimet · Roxgliptamet · Saphtagmin · Si2norm Plus · SIGLY-M · Simet · Sitacare · Sitacare Plus · Sitadase · Sitaform · Sitaform 1/50 · Sitag-M · Sitag-M 1000 · Sitagli Plus 1050 · Sitaglimin · Sitagmin · Sitagrand-M · Sitagrand-M 100/1000 · Sitaguard-M · Sitamac M 50/1000 · Sitamac M 50/500 · Sitamethyst 50/500 · Sitamin · Sitanova Plus 50/1000 · Sitanova Plus 50/500 · Sitanova-M 50/1000 · Sitaphil Plus · Sitaramin · Sitavetiz-M · Sitavex-MF · Sitavex-MF 50/500 · Sitazuca Mh 50/1000Sitazuca MH 50/1000 · Sitazuca MH 50/500 · Sitiformin · Skylimin · Staglimet · Stagmet · Strasimet · Su-Low · Taglimet · Taglipin Plus · Therasimet · Torsit M · Torsit M 100/1000 · Torsit M 1000 · Torsit M 50/500 · Volrea-M · Xitagmet · Zitamet · Zitamet Plus · Zitformin · Zynetra · Zynuvia Duo 50/500

Combination of oral blood glucose lowering drugs [dipeptidyl peptidase-4 (DPP-4) Inhibitor/Biguanide]; Antidiabetic agent [dipeptidyl peptidase 4 (DPP-4) inhibitor/Biguanidel]; and others PH FDA category
Fixed-dose combination.

Not for eGFR <45; CI if <30Rx · Prescription drug224 PH productsVAT-exempt (some products) Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID d19c7ed0-ad5c-426e-b2df-722508f97d67, version date August 11, 2026 (JANUMET · Merck Sharp & Dohme LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • JANUMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE JANUMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET [see Warnings and Precautions (5.2)].

JANUMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1) Limitations of Use: JANUMET should not be used in patients with type 1 diabetes.

(1) JANUMET has not been studied in patients with a history of pancreatitis. (1, 5.2)

Contraindications

  • eGFR below 30 mL/min/1.73 m2
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis
  • Serious hypersensitivity to sitagliptin or metformin
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS JANUMET is contraindicated in patients with: Severe renal impairment (eGFR below 30 mL/min/1.73 m²) [see Warnings and Precautions (5.1)]. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. History of a serious hypersensitivity reaction to JANUMET, sitagliptin, or metformin, such as anaphylaxis or angioedema [see Warnings and Precautions (5.7) and Adverse Reactions (6.2)].

Severe renal impairment: (eGFR below 30 mL/min/1.73 m²) (4) Metabolic acidosis, including diabetic ketoacidosis. (4) History of a serious hypersensitivity reaction to JANUMET, sitagliptin, or metformin, such as anaphylaxis or angioedema. (5.7, 6.2)

Dosing: Adult

  • Type 2 diabetes: One tablet (sitagliptin 50 mg with metformin 500 mg, 850 mg or 1 g) twice daily with meals; maximum sitagliptin 100 mg and metformin 2,000 mg per day
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Take JANUMET orally twice daily with meals. (2.1)
  • Individualize the dosage of JANUMET on the basis of the patient’s current regimen, effectiveness, and tolerability. (2.1)
  • The maximum recommended daily dose is 100 mg of sitagliptin and 2000 mg of metformin HCl. (2.1)
  • The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. (2.1)
  • The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For patients taking metformin HCl 850 mg twice daily, the recommended starting dose of JANUMET is 50 mg sitagliptin and 1000 mg metformin HCl twice daily. (2.1)
  • Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.2)
  • Do not use in patients with eGFR below 30 mL/min/1.73 m². JANUMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m². JANUMET may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. (2.3)
2.1 Recommended Dosing

2.1 Recommended Dosing Take JANUMET orally twice daily with meals. Individualize the dosage of JANUMET on the basis of the patient’s current regimen, effectiveness, and tolerability. The maximum recommended daily dose is 100 mg of sitagliptin and 2000 mg of metformin hydrochloride (HCl). Do not split or divide JANUMET tablets.

The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken.

For patients taking metformin HCl 850 mg twice daily, the recommended starting dose of JANUMET is 50 mg sitagliptin and 1000 mg metformin HCl twice daily.

2.2 Recommendations for Use in Renal Impairment

2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of JANUMET and periodically thereafter. JANUMET is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [see Contraindications (4) and Warnings and Precautions (5.1)]. JANUMET is not recommended in patients with an eGFR between 30 and less than 45 mL/min/1.73 m² because these patients require a lower dosage of sitagliptin than what is available in the fixed combination JANUMET product.

2.3 Discontinuation for Iodinated Contrast Imaging Procedures

2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue JANUMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart JANUMET if renal function is stable [see Warnings and Precautions (5.1)].

Dosing: Altered kidney function

This fixed combination pairs sitagliptin 50 mg with metformin 500 mg, 850 mg or 1 g. The US label contraindicates it below an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m2 (metformin, lactic acidosis) and does not recommend it at eGFR 30 to 44, because sitagliptin then needs a lower dose than the tablet provides. Below eGFR 45, use the components separately; below 30, metformin is contraindicated.

Kidney function measure: Label uses eGFR (mL/min/1.73 m2).

Show full dosing details
CrCl ≥60 mL/min
Usual: one tablet twice daily with meals; maximum sitagliptin 100 mg and metformin 2,000 mg per day. Check eGFR before starting and periodically (label).
CrCl 30–59 mL/min
eGFR 45–59: usual dose; consider a lower metformin dose if at risk of hypoperfusion or hypoxemia, and check eGFR every 3–6 months (ADA-KDIGO 2022). eGFR 30–44: not recommended (sitagliptin needs 50 mg/day, which the tablet cannot give); use the components separately: sitagliptin 50 mg daily plus metformin (do not start metformin at eGFR 30–45; if continuing, guidelines cap it at 1,000 mg/day).
CrCl 15–29 mL/min
Contraindicated below eGFR 30 (metformin; label). Use the components separately: sitagliptin alone at 25 mg once daily (sitagliptin label).
CrCl <15 mL/min (not on dialysis)
Contraindicated (eGFR <30; label). Use the components separately: sitagliptin alone at 25 mg once daily.
Hemodialysis (intermittent)
Contraindicated (metformin; eGFR <30). Use the components separately: sitagliptin alone at 25 mg once daily, any time relative to dialysis (sitagliptin label).
Peritoneal dialysis
Contraindicated (metformin; eGFR <30). Use the components separately: sitagliptin alone at 25 mg once daily.
CRRT
Not appropriate: metformin contraindicated in severe kidney impairment and acute kidney injury raises lactic acidosis risk (label).
  • Dialyzable? Metformin: yes, clearance up to 170 mL/min under good hemodynamic conditions. Sitagliptin: modestly, about 13.5% removed in a 3- to 4-hour session; peritoneal dialysis removal unknown (label 10).
  • Monitoring eGFR before starting and at least yearly; more often if eGFR <60 or at risk. Stop at or before iodinated contrast if eGFR 30–60, liver disease, alcoholism, heart failure or intra-arterial contrast; recheck eGFR at 48 hours (label 2.3). Hold during acute illness, dehydration or surgery. Vitamin B12 with long-term use. Hypoglycemia with insulin or sulfonylureas.
Children (kidney dosing)
eGFR ≥60
Not approved for children; kidney dosing not applicable.
eGFR 30–59
Not approved for children; kidney dosing not applicable.
eGFR 15–29
Not approved for children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not approved for children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not approved for children; kidney dosing not applicable.
Peritoneal dialysis
Not approved for children; kidney dosing not applicable.
CRRT
Not approved for children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of JANUMET and periodically thereafter. JANUMET is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [see Contraindications (4) and Warnings and Precautions (5.1)]. JANUMET is not recommended in patients with an eGFR between 30 and less than 45 mL/min/1.73 m² because these patients require a lower dosage of sitagliptin than what is available in the fixed combination JANUMET product.

8.6 Renal Impairment JANUMET JANUMET is not recommended in patients with an eGFR between 30 and less than 45 mL/min/1.73 m² because these patients require a lower dosage of sitagliptin than what is available in the fixed dose combination JANUMET product. JANUMET is contraindicated in severe renal impairment, patients with an eGFR below 30 mL/min/1.73 m² [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Sitagliptin Sitagliptin is excreted by the kidney, and sitagliptin exposure is increased in patients with renal impairment [see Clinical Pharmacology (12.3)]. Metformin Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment.

Patients with Renal Impairment JANUMET Studies characterizing the pharmacokinetics of sitagliptin and metformin after administration of JANUMET in renally impaired patients have not been performed [see Dosage and Administration (2.2)]. Sitagliptin An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to less than 45 mL/min/1.73 m², and an approximately 4-fold increase was observed in patients with severe renal impairment including patients with end-stage renal disease (ESRD) on hemodialysis, as compared to normal healthy control subjects [see Dosage and Administration (2.2)].

Metformin In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [see Contraindications (4) and Warnings and Precautions (5.1)].

Dosing: Hepatic impairment

8.7 Hepatic Impairment Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. JANUMET is not recommended in patients with hepatic impairment [see Warnings and Precautions (5.1)].

US FDA label

Dosing: Pediatric

Approved ages
Not established in pediatric patients (label 8.4).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of JANUMET have not been established in pediatric patients. Three 20-week double-blind, placebo-controlled studies each with 34-week extensions were conducted to evaluate the efficacy and safety of sitagliptin in 410 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes, with or without insulin therapy (HbA1c 6.5-10% for patients not on insulin, HbA1c 7-10% for patients on insulin).

At study entry, patients in study 1 were not treated with oral antihyperglycemic agents; patients in studies 2 and 3 were on maximally tolerated metformin therapy. The primary efficacy endpoint was the change from baseline in HbA1c after 20 weeks of therapy. The pre-specified primary efficacy analyses included data from study 1 and pooled data from studies 2 and 3, regardless of glycemic rescue or treatment discontinuation.

In both efficacy analyses, the effect of treatment with sitagliptin was not significantly different from placebo. In study 1, the mean baseline HbA1c was 7.5%, and 12% of patients were on insulin therapy. At week 20, the change from baseline in HbA1c in patients treated with sitagliptin (N=95) was 0.06% compared to 0.23% in patients treated with placebo (N=95), a difference of -0.17% (95% CI: -0.62, 0.28).

In studies 2 and 3, the mean baseline HbA1c was 8.0%, 15% of patients were on insulin and 72% were on metformin HCl doses of greater than 1,500 mg daily. At week 20, the change from baseline in HbA1c in patients treated with sitagliptin (N=107) was -0.23% compared to 0.09% in patients treated with placebo (N=113), a difference of -0.33% (95% CI: -0.70, 0.05).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use JANUMET In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Renal function should be assessed more frequently in elderly patients [see Contraindications (4), Warnings and Precautions (5.1, 5.4) and Clinical Pharmacology (12.3)].

Sitagliptin Of the total number of subjects (N=3884) in clinical studies of sitagliptin, 725 patients were 65 years and over, while 61 patients were 75 years and over. No overall differences in safety or effectiveness were observed between subjects 65 years and over and younger subjects. While this and other reported clinical experience have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.

Metformin Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and young patients.

Dosage forms

Philippines

  • Film-coated tablet: 1 g/50 mg, 50 mg 500 mg, 50 mg/1 g, 50 mg/1000 mg, 50 mg/500 mg, 50 mg/850 mg, 100 mg/1 g, 500 mg, 500 mg/50 mg
  • Extended-release film-coated tablet: 1 g/100 mg, 100 mg/1 g
  • Extended-release tablet: 100 mg/1 g
  • Tablet: 50 mg/500 mg, 200 mg
  • Extended-release fc tablet: 100 mg/1 g
  • Film-coated tabletet: 50 mg/500 g

Registered products in the Philippines

224 products registered with the Food and Drug Administration (FDA) Philippines list Metformin + Sitagliptin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Sitagliptin (as phosphate monohydrate) + Merformin hydrochloride (1 product) · Sitagliptin + Metforinin Hydrochloride (1 product) · Sitagliptin (as Phosphate) + Metformin HC1 (1 product) · Sitagliptin (As Phosohate Monohydrate) + Metformin Hydrochlorde (1 product) · Sitagliptin (as Phosphate Monohydrate) - Metformin Hydrochloride (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products224
Philippine FDA-registered products for Metformin + Sitagliptin
Package insert
Acantha MaxSitagliptin (as Phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/ Alu blister pack x 10’s (Box of 100’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-15916-01
Sep 30, 2029
Acantha PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-11848-01
May 10, 2027
Acantha PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-15915-01
Sep 30, 2029
Adivia MetSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Our Drugstrore Man Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-12817-02
Nov 29, 2026
Adivia MetSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-12817
Nov 29, 2031
Adivia Met XRSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg / 1 g Extended Release Fc TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-18588
Aug 4, 2031
AgmetriaMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
500 mg/ 50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
J.M. Tolmann Laboratories Inc.Philippines
Medirich Pharma Distribution Corp.
DRP-12688-01
Sep 22, 2027
AltodiabSitagliptin + Metformin Hydrochloride
50 mg/1000 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Scilife Pharma (Pvt.) Ltd.Pakistan
Altomed Pharmaceuticals, Inc.Importer: S.M.H.P. Marketing & Consultancy
DRP-12905-01
Oct 27, 2027
AltuxermetSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Sandoz Private LimitedIndia
Sandoz Philippines Corporation
DRP-16998
Sep 5, 2030
AltuxermetSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Sandoz Private LimitedIndia
Sandoz Philippines Corporation
DRP-16999
Sep 5, 2030
Amaziptin-M 1000Sitagliptin (as hydrochloride) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's ( Box of 30's )
RxVAT-exempt
Hetero Labs Limited (Unit-V, Block-VB)India
Mega Lifesciences Limited Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-10943-02
Dec 21, 2026
Amaziptin-M 500Sitagliptin (As Phosphate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu / Alu Blister Pack X 10's (Box of 30's)
RxVAT-exempt
Annora Pharma Private LimitedIndia
Mega Lifesciences Limited Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-17203-01
Oct 20, 2030
Ambetria-MSitagliptin (as Phosphate) + Metformin HC1Variant spelling
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16623
May 21, 2030
Ambetria-M 500Sitagliptin (as Phosphate) + Metformin HCl
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16624
May 21, 2030
AzentinSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Kodapharm Med Corp.Importer: Teramedix Pharma Trading Inc.
DRP-13229-07
Jan 5, 2028
Co-Zincretin 50/ 500Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Zydus Healthcare Philippines Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-11
Jan 5, 2028
Co-Zincretin 50/1000Sitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-12059-4
Jun 6, 2027
Co-Zincretin 50/500Sitagliptin (as phophate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu /Alu blister pack of 10’s (Box of 20’s, 30’s and 100’s)
RxVAT-exempt
—
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12881-01
Oct 24, 2027
Co-Zincretin XR 100/1000Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg/ 1g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Zydus Healthcare Philippines Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13230-06
Jan 5, 2028
Co-Zincretin XR 100/1000Sitagliptin (as monohydrate phosphate) + Metformin Hydrochloride
100 mg/1 g Extended Release Film-Coated TabletAlu-Pvc/Pvdc Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-18409
Jul 2, 2031
CurasitSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Curasave PharmaImporter: Teramedix Pharma Trading Inc.
DRP-13229-10
Jan 5, 2028
CuroViaSitagliptin (as phosphate monohydrate) + Merformin hydrochlorideVariant spelling
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Sai Mirra Innopharm Pvt. Ltd.India
Shanghai Pharma (Philippines) Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-11
Jun 2, 2027
DeglucomSitagliptin (as phosphate) + Metformin hydrochloride
50 mg /500 mg Film-Coated TabletAlu/Alu Blister pack x 10’s (Box of 30’s)
RxVAT-exempt
Flourish PharmaIndia
NAB Trading Corp.Importer: Biophil Medical Equipment And Supplies Trading
DRP-16228-01
Jan 7, 2030
Diaglip Duo 500Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg /500 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Iberica Verheilen Pharmaceuticals Group Corp.Importer: AMB HK Enterprises Inc.
DRP-15915-04
Sep 30, 2029
Duoglica Plus 50/ 500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's, Box of 30's, and Box of 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12881-05
Oct 24, 2027
EmpalinSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
100 mg/1 g Extended-Release TabletAlu/Alu Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17049
Sep 23, 2030
Exesit-MSitagliptin (As Phosohate Monohydrate) + Metformin HydrochlordeVariant spelling
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 100's)
Rx
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-15916
Aug 4, 2031
Exesit-MSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and Box of 100’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises IncTrader: N/A
DRP-15915
Aug 4, 2031
Fliptin MaxSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg /1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Glorious Dexa Mandaya, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14292-02
Aug 10, 2028
Fliptin MaxSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Glorious Dexa Mandaya, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14294-02
Aug 10, 2028
ForglipSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg/1g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13230-07
Jan 5, 2028
ForglipSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50mg / 500mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-24
Jan 5, 2028
GleeflorSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg / 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Pharma Hub CorporationImporter: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-09
Jun 2, 2027
GleeforSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharma Hub CorporationImporter: Teramedix Pharma Trading Inc.
DRP-13229-15
Jan 5, 2028
GliforgeSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100mg/1 g Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-13230
Jan 5, 2028
GliforgeSitagliptin (as Phosphate monohydrate) + Metformin Hydrochloride
50mg/500mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-13229
Jan 5, 2028
GlimeferSitagliptin Phosphate + Metformin HCl
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's & 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
Ferma Drug Enterprises
DRP-16596-02
May 13, 2030
GlipcorSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Novocore Pharma Inc.Importer: I.E.Medica, Inc.
DRP-13279-02
Jan 19, 2030
GlipgludinSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Medchoice Endocrine Group, Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-09
Jan 5, 2028
Glipiformin 50/500Sitagliptin (As Phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack X 10's. (Box of 30's and Box of 100's)
RxVAT-exempt
Aksharam Pharma Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18207
May 28, 2031
Glipiformin 50/850Sitagliptin (As Phosphate) + Metformin Hydrochloride
50 mg/850 mg Film-Coated TabletAlu/Alu Blister Pack x 10's. (Box of 30's and Box of 100's)
RxVAT-exempt
Aksharam Pharma Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18208
May 28, 2031
Glipstar-1000Sitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50mg/1g Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Suhitas Pharmaceuticals Inc.
DRP-12059
Jun 6, 2027
Gliptina PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
HealthPrescription, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037
Jun 2, 2032
Glucadrop PlusSitagliptin (as phosphate monohydarte) + Metformin Hydrochloride
50 mg /500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: Medethix, Inc.
DRP-11150-02
Feb 8, 2027
GlucentraSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad - Warangal Highway Bhongir Telangana 508116 India
TGP Pharma Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11948-02
Aug 22, 2030
GlucodropSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50mg/1000mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-18466
Jul 20, 2031
GlucodropSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50mg/850mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-18467
Jul 20, 2031
GlucomedSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's, Box of 30's and Box of 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Medlink Pharma Phils., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12881-03
Oct 24, 2027
Glucomed PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Medlink Pharma Phils., Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-04
Jun 2, 2032
GluconavMetformin hydrochloride + Sitagliptin phosphate
500 mg/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
JNC Pharmaceuticals CorporationImporter: Pharmakon Biotec, Inc.
DRP-15402-03
Jul 2, 2029
GlucositaSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-17
Jan 5, 2028
GlusimetSitagliptin + Metforinin HydrochlorideVariant spelling
50mg/1000mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
Rx
Scilife Pharma (Pvt.) Ltd.Pakistan
SMHP Pharmaceuticals Incorporated
DRP-12905
Oct 27, 2027
Gluviance-MSitagliptin(as phosphate monohydrate) + Metformin Hydrochloride
50mg/500mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt., Ltd.India
Rule Med Pharma Corp.Importer: Teramedix Pharma Trading Inc.
DRP-13229-19
Jan 5, 2028
GlycoppexMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
500 mg / 50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
J.M. Tolmann Laboratories, Inc.Philippines
Appex MD's Pharmaceuticals Inc.
DRP-12688-02
Sep 22, 2027
GlysicareSitagliptin (as phosphate monohydrate)+Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.174101
Medcare PharmaceuticalsImporter: Teramedix Pharma Trading Inc.
DRP-13229-23
Jan 5, 2028
Glysiptin PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Totalcare Pharma Inc.Trader: Dr. Zen's Research, Inc.
DRP-14294-03
Aug 10, 2028
Glyxera MetMetformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Ajanta Pharma Philippines IncImporter: Ambica International Corporation
DRP-12328-05
Jul 15, 2032
Glyxera MetSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sai Parenterals Ltd.India
Ajanta Pharma Philippines Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11948-01
Aug 22, 2030
Glyxera Met XRSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride (in extended release form)
50mg/1g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Windlas Biotech Limited (Plant 2)India
Ajanta Pharma Philippines Inc.Importer: Synergia Health Care & Life Sciences, Inc.
DRP-17435-01
Dec 15, 2030
Glyxera Met XRSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride (in extended release form)
50mg/500mg FIlm-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Windlas Biotech Limited (Plant 2)India
Ajanta Pharma Philippines Inc.Importer: Synergia Health Care & Life Sciences, Inc.
DRP-17434-01
Dec 15, 2030
IndousSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
All-Bio Pharma, Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-01
Jan 5, 2028
Instadip-M 100/1000Sitagliptin (as phosphate) + Metformin hydrochloride
100 mg/1 g Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sun Pharmaceutical Industries Limited.India
Sun Pharma Philippines, Inc.
DRP-16695
Jun 16, 2030
Instadip-M/50/500Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride (in extended-release form)
50mg/500mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-18773
Sep 3, 2031
Jantin-MMetformin hydrochloride + Sitagliptin phosphate
500 mg / 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15402-02
Jul 2, 2029
JanumetSitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg 500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's) Alu/Alu Blister Pack x 7's (Box of 7's) [Physician's Sample]
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-16031
Oct 18, 2029
JanumetSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 7's Box of 28's; Alu/Alu Blister Pack x 7's Box of 7's (Physician Sample)
RxVAT-exempt
Patheon Puerto Rico, Inc.USA
Merck Sharp & Dohme (I.A.) LLC
DRP-4012
Mar 14, 2029
JanumetSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's); Alu/Alu Blister Pack x 7's Box of 7's (Physician Sample)
RxVAT-exempt
Patheon Puerto Rico, Inc.USA
Merck Sharp & Dohme (I.A.) LLC
DRP-4010
Mar 14, 2029
JanumetSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride
50 mg/ 850 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Patheon Puerto Rico, Inc.USA
Merck Sharp & Dohme (I.A.) LLC
DRP-4011
Mar 14, 2029
JanumetSitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's) Alu/Alu Blister Pack x 7's (Box of 7's) [Physician's Sample]
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-16030
Oct 18, 2029
JanumetSitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg/850 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-16115
Nov 4, 2029
Janumet XRSitagliptin + Metformin Hydrochloride
100 mg/1 g Extended Release Film-Coated TabletHDPE White Plastic Bottle (Bottle of 28's); HDPE White Plastic Bottle (Bottle of 30's); HDPE White Plastic Bottle (Bottle x 7's (Physician's sample))
RxVAT-exempt
AIAC International Pharma, LLCUSA
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5360
Jun 23, 2029
Janumet XRSitagliptin Phosphate + Metformin Hydrochloride
100 mg/1 g Extended-Release Film-Coated TabletWhite HDPE Plastic Bottle Bottle x 28's; White HDPE Plastic Bottle Bottle x 30's
RxVAT-exempt
MSD International GmbH (Puerto Rico Branch)USA
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-9578
Mar 4, 2031
JavametSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Nucare Pharmaceutical Products DistributionImporter: Teramedix Pharma Trading Inc.
DRP-13229-12
Jan 5, 2028
Kozta PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
UNILAB, INC.Importer: AMB HK Enterprises Inc.
DRP-15915-03
Sep 30, 2029
Kozta Plus XRSitagliptin (as phosphate) + Metformin hydrochloride
100 mg/ 1 g Extended-Release TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Unilab, Inc.Importer: Sun Pharma Philippines, Inc.
DRP-16695-01
Jun 16, 2030
KoztaTM PlusSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/1g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals Limited.India
UNILAB, Inc.
DRP-13051
Nov 23, 2027
KoztaTM PlusSitagliptin (as phosphate) + Metformin Hydrochloride.
50 mg/850 mg Film-Coated Tablet4 Alu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
UNILAB, Inc.
DRP-15039
Apr 17, 2029
LiptimetSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg/1 g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Radbuster Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13230-02
Jan 5, 2028
LiptimetSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Radbuster Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-05
Jan 5, 2028
Lupigliptin PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50mg/500mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Medspecialty, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-12817-01
Nov 29, 2026
MaedgliptinSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Maed Pharma CorporationImporter: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-08
Jun 2, 2027
MestisSitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50mg/1g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Amediqo Phils., Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-12059-03
Jun 6, 2027
MetagliptSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride (in extended-release form)
50mg/1g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Windlas Biotech Limited (Plant 2)India
Synergia Health Care & Life Sciences, Inc.
DRP-17435
Dec 15, 2030
METAGLIPTINSitagliptin Phosphate + Metformin HCl
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's & 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical And Pharma Inc.
DRP-16596-01
May 13, 2030
MetasitMetformin hydrochloride + Sitagliptin phosphate
1 g/100 mg Extended-Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-15403
Jul 2, 2029
MetasitMetformin hydrochloride + Sitagliptin phosphate
500 mg/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-15402
Jul 2, 2029
MetglipzinSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-07
Jun 2, 2027
MetglynSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50mg /500mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec, Inc.Importer: Teramedix Pharma Trading, Inc.
DRP-13229-20
Jan 5, 2028
Metromin PlusSitagliptin Phosphate + Metformin HCl
50 mg/500 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's & 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16596
May 13, 2030
Metromin Plus 50/1000Sitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu-Alu Blister Pack X 10'S (Box Of 30'S, 50'S And 100'S)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.,Philippines
—
DRP-19029
Oct 19, 2031
Metromin Plus 50/850Sitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg/850mg Film-Coated TabletAlu-Alu Blister Pack X 10'S (Box Of 30'S, 50'S And 100'S)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.,Philippines
—
DRP-19031
Oct 19, 2031
Metsaphtin - 50/500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 35's) and 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-11948
Aug 22, 2030
Metsaphtin - 50/850Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/850 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 35's) and 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals LtdIndia
Nelpa Lifesciences, Inc.
DRP-11947
Aug 28, 2030
MetsiglobSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride
50 mg/500 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-18540
Jul 27, 2031
MetsitaSitagliptin (as hydrochloride) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit-V, Block-VB)India
2MG IncorporatedImporter: Camber Pharmaceuticals, Inc.
DRP-10943-01
Dec 21, 2026
NeoglipSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
SEA-King Pharma Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-03
Jan 5, 2028
NoneSitagliptin (as phosphate) + Metformin Hydrochloride
100 mg/1 g Film-Coated TabletAlu/ Alu Blister Pack x 7's (Box of 35's); Alu/ Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.
DRP-12000-01
May 27, 2027
NoneSitagliptin (as hydrochloride) + Metformin Hydrochloride
50 mg / 1 g Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Watsons Personal Care Stores (Philippines), Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-10943-04
Dec 21, 2026
NoneSitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50 mg / 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-12059-02
Jun 6, 2027
NoneSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg / 1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14292-01
Aug 10, 2028
NoneSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/ Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14294-01
Aug 10, 2028
NoneSitagliptin (as hydrochloride) + Metformin Hydrochloride
50 mg/ 850 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Watsons Personal Care Stores (Philippines), Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-15078-01
Apr 17, 2029
NoneSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-01
Jun 2, 2027
NoneSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-03
Jun 2, 2027
NoneSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14292-03
Aug 10, 2028
NoneSitagliptin (as phosphate) + Metformin HCl
50 mg/1g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 35's) and 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceutcials Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12279-01
Jul 7, 2027
NoneSitagliptin (as phosphate monohydrate)+Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India 174101
Reta DrugImporter: Teramedix Pharma Trading Inc.
DRP-13229-22
Jan 5, 2028
noneSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-13890
May 11, 2028
NoneMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
500 mg/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
Getz Pharma (Phils.), Inc.Importer: Amb Hk Enterprises Inc.
DRP-14893-02
Feb 22, 2029
Novasit-M 50/1000Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.
DRP-15251
May 31, 2036
Novasit-M 50/500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-coated TabletAlu/Alu blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.
DRP-13278
Jan 19, 2030
OP-Sita DuoSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Orient Pearl Med Pharma, Inc.Importer: AMB HK Enterprises Inc.
DRP-11848-05
May 10, 2027
Philsitz-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-11847-02
May 10, 2027
Philsitz-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-11848-02
May 10, 2027
PonicorSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100mg / 1g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13230-11
Jan 5, 2028
Premiliptin PlusMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
500 mg/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-14893-01
Feb 22, 2029
Retaformin PlusSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's, Box of 30's and Box of 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-12881-02
Oct 24, 2027
RetaglimetMetformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Reta DrugImporter: Ambica International Corporation
DRP-12328-03
Jul 15, 2032
RoxgliptametSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India 174101
Roxwester International Corp.Importer: Teramedix Pharma Trading Inc.
DRP-13229-25
Jan 5, 2028
S-MetprimeSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg /1 g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Life and Health Source Pharmaceutical Distribution Co.Importer: Teramedix Pharma Trading Inc.
DRP-13230-08
Jan 5, 2028
S-MetprimeSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Life and Health Source Pharmaceutical Distribution Co.Importer: Teramedix Pharma Trading Inc.
DRP-13229-14
Jan 5, 2028
SaphtagminSitagliptin (as phosphate) + Metformin Hydrochloride
200 mg TabletAlu/Alu Blister Pack x 7's (Box of 35's) Alu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
Ollen Pharma Trading Inc.,
DRP-12000
Sep 15, 2030
Si2norm PlusSitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50 mg / 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Orange Biotec Inc.Importer: Suhitas Pharmaceutical Inc.
DRP-12059-06
Jun 6, 2027
SIGLIP-MetSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc.
DRP-15916-02
Sep 30, 2029
SIGLIP-MetSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc.
DRP-15915-02
Sep 30, 2029
SIGLY-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-coated Tablet
RxVAT-exempt
Biodeal Pharmaceuticals LimitedIndia
Neos-King Pharma Inc.
DRP-17638
Feb 10, 2031
SilametSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100mg/ 1g Extended Release Film- Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. LtdIndia
Ellebasy Medicale Group Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13230-10
Jan 5, 2028
SilametSitagliptin (as phosphate monohydrate ) + Metformin Hydrochloride
50 mg/500 mg Film- Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India 174101
Ellebasy Medicale Group Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-21
Jan 5, 2028
SimetSitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-12059-01
Jun 6, 2027
SitacareSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14294-04
Aug 10, 2028
Sitacare PlusSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Dr. Zen's Research, Inc.
DRP-14292-04
Aug 10, 2028
SitadaseSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Macropharma CorporationImporter: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-10
Jun 2, 2027
SitaformSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50mg/500mg film-coated tabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
EuroAsia Pharmaceuticals Inc.
DRP-12238
Jul 1, 2032
Sitaform 1/50Metformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Euroasia Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-12328-02
Jul 15, 2032
Sitag-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Medethix, Inc.
DRP-11150
Feb 8, 2027
Sitag-M 1000Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1000 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Medethix, Inc.
DRP-14274
Aug 9, 2030
Sitagard-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Healol Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-11847-05
May 10, 2027
Sitagard-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Healol Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-11848-06
May 10, 2027
Sitagli Plus 1050Metformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Ambica International Corporation
DRP-12328
Jul 15, 2032
SitagliminSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's, Box of 30's, Box of 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc.
DRP-12881-04
Oct 24, 2027
Sitaglo - M 50/850Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/850mg Film Coated TabletAlu/PVC-PE/PVDC Opaque Blister x 14's (Box of 56's)
RxVAT-exempt
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18500
Jul 22, 2031
Sitaglo - M 50/850Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/850mg Film Coated TabletWhite Opaque HDPE Sealed with Cap x 30's and 100's (Box of 1's)
RxVAT-exempt
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18501
Jul 22, 2031
Sitaglo M- 50/1000Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1000 mg Film Coated TabletWhite Opaque HDPE Bottle Sealed with Cap x 30's and 100's (Box of 1's)
RxVAT-exempt
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18482
Jul 21, 2031
Sitaglo M- 50/1000Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1000 mg Film Coated TabletAlu PVC/PE/PVDC Opaque Blister Pack x 14's (Box of 56's)
RxVAT-exempt
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18483
Jul 21, 2031
Sitaglo M- 50/1000Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1000 mg Film Coated TabletALu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18484
Jul 21, 2031
SitagminSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
RL Pharma Enterprises Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-16
Jan 5, 2028
Sitagrand-MSitagliptin(as phosphate monohydrate) + Metformin Hydrochloride
50mg/500mg Film-Coated TabletAlu-Alu blister packs x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Grandis Pharma IncorporatedImporter: Teramedix Pharma Trading Inc.
DRP-13229-18
Jan 5, 2028
Sitagrand-M 100/1000Sitagliptin(as phosphate monohydrate) + Metformin Hydrochloride
100mg/1g Extended Release Film-Coated TabletAlu-Alu blister pack x 10's (Box of 100's and 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Grandis Pharma IncorporatedImporter: Teramedix Pharma Trading Inc.
DRP-13230-09
Jan 5, 2028
Sitaguard-MSitagliptin (as Phosphate Monohydrate) - Metformin HydrochlorideVariant spelling
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Theon Pharmaceuticals LimitedIndia
Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-12059-05
Jun 6, 2027
Sitajack-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceutical LimitedIndia
Jackpharma Inc.Importer: MedEthix Inc.
DRP-11150-01
Feb 8, 2027
Sitajack-MSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Jackpharma Inc.Importer: I.E. Medica, Inc.
DRP-13278-01
Jan 19, 2030
Sitakem-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg/ 1 g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alkem Laboratories CorporationImporter: Teramedix Pharma Trading Inc.
DRP-13230-04
Jan 5, 2028
Sitakem-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alkem Laboratories CorporationImporter: Teramedix Pharma Trading Inc.
DRP-13229-08
Jan 5, 2028
Sitamac M 50/1000Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Cold Forming Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY48553
Jan 5, 2028
Sitamac M 50/500Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Cold Forming Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY48552
Jan 5, 2028
SitametMetformin Hydrochloride + Sitagliptin (As Phosphate Monohydrate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: J.M. Tolmann Laboratories, Inc.
DRP-18292
Jun 4, 2031
SitametMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
500 mg/50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
J.M. Tolmann Laboratories Inc.Philippines
—
DRP-12688
Sep 22, 2027
Sitamethyst 50/500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc.
DRP-13279-01
Jan 19, 2030
SitaminSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alpha Farmaceutico Corp.Importer: Teramedix Pharma Trading Inc.
DRP-13229-04
Jan 5, 2028
Sitanav PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg/ 1g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Rexmed Pharmaceutical SalesImporter: Teramedix Pharma Trading Inc.
DRP-13230-01
Jan 5, 2028
Sitanav PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Rexmed Pharmaceutical SalesImporter: Teramedix Pharma Trading Inc.
DRP-13229-02
Jan 5, 2028
Sitanova Plus 50/1000Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/1 g Film Coated TabletAlu/Alu Blister Pack x 6's (Box of 18's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Medinova Pharmaceutical Inc.
DRP-16292
Jan 31, 2030
Sitanova Plus 50/500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Medinova Pharmaceutical, Inc.
DRP-12881
Oct 24, 2027
Sitanova-M 50/1000Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc.
DRP-15252
May 31, 2031
Sitaphil PlusMetformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Phil Asia Pharma IncImporter: Ambica International Corporation
DRP-12328-01
Jul 15, 2032
SitaplusMetformin hydrochloride + Sitagliptin (as phosphate monohydrate)
1 g / 50 mg Film-Coated TabletAlu / Alu blister Pack x 7 (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma Inc.
DRP-15692
Aug 10, 2028
SitaplusMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
1 g/50 mg Film-Coated TabletAlu/Alu blister pack x 7 (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY48839
Aug 10, 2028
SitaplusMetformin Hydrochloride + Sitagliptin (as phosphate monohydrate)
500 mg/50 mg Film-Coated TabletAlu/Alu blister pack x 7 (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY48840
Aug 10, 2028
SitaraminSitagliptin (as phosphate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister pack of 10's (Box of 30's)
RxVAT-exempt
Flourish PharmaIndia
Speed Med Pharmaceuticals Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-18038
Apr 29, 2031
Sitavetiz-MSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
TGP Pharma Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11948-03
Aug 22, 2030
Sitavex-MFSitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49382
Apr 22, 2030
Sitavex-MF 50/500Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/PVC Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49472
Aug 22, 2030
Sitazit-MSitagliptin (As Hydrochloride) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit-V, Block-VB)India
Camber Pharmaceuticals, Inc.
DRP-10943
Dec 21, 2026
Sitazit-MSitagliptin (as hydrochloride) + Metformin Hydrochloride
50 mg/850 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-15078
Apr 17, 2029
Sitazuca Mh 50/1000Sitazuca MH 50/1000Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mylan Laboratories Limited.India
Viatris Pharmaceuticals, Inc.
DR-XY49415
Jun 10, 2030
Sitazuca MH 50/500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc
DR-XY49416
Jun 10, 2030
SitiforminSitagliptin + Metformin (as hydrochloride)
50 mg/500 mg Film-coated TabletAlu/Alu Blister Foil Pack x 14's (Box of 14's)
RxVAT-exempt
Mcolson Research Laboratories (Pvt.) Ltd. DistPakistan
Sahar International Trading Inc.
DRP-17165
Oct 9, 2030
SkyliminSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's, Box of 30's, Box of 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc.
DRP-12881-07
Oct 24, 2027
StaglimetSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareKyrgyzstan
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-17057
Oct 7, 2030
StagmetSitagliptin (as phosphate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-16228
Jan 7, 2030
StrasimetSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Bio-Strata Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-06
Jun 2, 2032
Su-LowSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
RM Lorenzo Pharma & Distribution Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-13
Jan 5, 2028
TaglimetSitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride
50mg/1g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Reta DrugImporter: Suhitas Pharmaceuticals, Inc.
DRP-12059-07
Jun 6, 2027
Taglipin PlusSitagliptin Phosphate + Metformin HCl
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's & 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16596-03
May 13, 2030
TherasimetSitagliptin (as phosphate) + Metformin Hydrochloride
50 mg / 500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 20's; 30's and 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Therapevo Farmaco Pharma and Medical Supplies TradingImporter: Medinova Pharmaceutical, Inc.
DRP-12881-06
Oct 24, 2027
Tiglipza PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
100 mg/1 g Extended Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Lakeside Pharmaceuticals Phil., Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13230-03
Jan 5, 2028
Tiglipza PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Lakeside Pharmaceuticals Phil., Inc.Importer: AMB HK Enterprises Inc.
DRP-15916-04
Sep 30, 2029
Tiglipza PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. LtdIndia
Lakeside Pharmaceuticals Phil., Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13229-06
Jan 5, 2028
Torsit MSitagliptin (as hydrochloride) + Metformin Hydrochloride
50 mg / 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Torrent Pharma Philippines, Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-10943-03
Dec 21, 2026
Torsit M 100/1000Sitagliptin (as phosphate) + Metformin Hydrochloride
100 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Sai Parenterals Ltd.India
Torrent Pharma Philippines, Inc.Importer: Ollen Pharma Trading Inc.
DRP-12000-02
Sep 15, 2030
Torsit M 1000Metformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48367
Sep 22, 2027
Torsit M 50/500Sitagliptin (as phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Sai Parenterals Ltd.India
Torrent Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11948-05
Aug 22, 2030
TreviametMetformin Hydrochloride + Sitagliptin (as phosphate. monohydrate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: AMB HK Enterprises Inc.
DRP-14894
Feb 22, 2029
TreviametMetformin Hydrochloride + Sitagliptin (as phosphate. monohydrate)
500 mg/50 mg Film- Coated TabletsAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: AMB HK Enterprises Inc.
DRP-14893
Feb 22, 2029
UnbrandedMetformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-12328-04
Jul 15, 2032
UnbrandedMetformin hydrochloride + Sitagliptin (as phosphate)
1 g/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Regimed Pharmaceutical DistributorImporter: Ambica International Corporation
DRP-12328-06
Jul 15, 2032
UnbrandedSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-02
Jun 2, 2032
UnbrandedSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-12037-05
Jun 2, 2032
UnometSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
—
Healol Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-11847-07
May 10, 2027
UnometSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Healol Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-11848-08
May 10, 2027
UnometSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu blister pack x 10’s (Box of 100’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Healol Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-15915-05
Sep 30, 2029
VelmetiaSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride
50 mg/ 1g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's); Alu/Alu Blister Pack x 7's [Box of 7's (Physician Sample)]
RxVAT-exempt
Patheon Puerto Rico, Inc.USA
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-4012-01
Mar 14, 2029
VelmetiaSitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's); Alu/Alu Blister Pack x 7's (Box of 7's) [Physician's Sample]
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-16030-01
Oct 18, 2029
VelmetiaSitagliptin (as Phosphate) + Metformin Hydrochloride
50 mg/500 g Film-Coated TabletetAlu/Alu Blister Pack x 7's (Box of 28's); Alu/Alu Blister Pack x 7's (Box of 7's) [Physician's Sample]
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-16031-01
Oct 18, 2029
VelmetiaSitagliptin (as Monohydrate Phosphate) + Metformin Hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's); Alu/Alu Blister Pack x 7's [Box of 7's (Physician Sample)]
RxVAT-exempt
Patheon Puerto Rico, Inc.USA
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-4010-01
Mar 14, 2029
Vilantra PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg / 500 mg Film-coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The ACME Laboratories Ltd.Bangladesh
Oxpharm Inc.Importer: Euro Generics International Philippines, Inc.
DRP-17902-01
Mar 31, 2031
Vilantra PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The ACME Laboratories Ltd.Bangladesh
Oxpharm Inc.Importer: Euro Generics International Philippines, Inc.
DRP-17901-01
Mar 31, 2031
Volrea-MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-11847
May 10, 2032
Xiglip MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: AMB HK Enterprises Inc.
DRP-11847-04
May 10, 2032
Xiglip MSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: AMB HK Enterprises Inc.
DRP-11848-04
May 10, 2027
Xiglip MSitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
RxVAT-exempt
Base Medico Private LimitedIndia
AMB HK Enterprises, Inc.
DRP-18907
Sep 29, 2031
XitagmetSitagliptin (as phosphate) + Metformin Hydrochloride
50mg/500mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Vivilon Pharmaceuticals Inc.
DRP-13279
Jan 19, 2030
ZitametSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-11848-03
May 10, 2027
Zitamet PlusSitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg/ 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-11847-03
May 10, 2027
ZitforminMetformin hydrochloride + Sitagliptin phosphate
500 mg/50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
RoDaise Pharma Distributor CorporationImporter: Pharmakon Biotec Inc.
DRP-15402-01
Jul 2, 2029
ZynetraSitagliptin (As Phosphate Monohydrate) + Metformin Hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Zhejiang Zhongtong Pharmaceutical Co.,Ltd.India
AMB HK ENTERPRISES INC.
DRP-19034
Oct 19, 2031
Zynuvia Duo 50/500Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50/500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18511
Jul 27, 2031
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin. Hydrochloride
50 mg / 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Medethix, Inc.
DRP-13176
Dec 14, 2027
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride
50 mg /500 mg Film-Coated TabletAlu/Alu Blister x 10's ( Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Medethix, Inc.
DRP-13908
May 17, 2028
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-14291
Aug 10, 2028
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/1 g Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen's Research, Inc.
DRP-14292
Aug 10, 2028
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DR-XY47569
Nov 29, 2026
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-14293
Aug 10, 2028
(no brand name)Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride
50 mg/500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen's Research, Inc.
DRP-14294
Aug 10, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Tablets: sitagliptin 50 mg and metformin HCl 500 mg tablets are light pink, capsule-shaped, film-coated tablets with “575” debossed on one side. sitagliptin 50 mg and metformin HCl 1000 mg tablets are red, capsule-shaped, film-coated tablets with “577” debossed on one side. JANUMET Tablets: sitagliptin 50 mg and metformin HCl 500 mg tablets sitagliptin 50 mg and metformin HCl 1000 mg tablets (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Lactic Acidosis: See boxed warning. (5.1)
  • Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue JANUMET. (5.2)
  • Heart Failure: Has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JANUMET in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. (5.3)
  • Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Before initiating JANUMET and at least annually thereafter, assess renal function. (5.4)
  • Vitamin B12 Deficiency: Metformin may lower vitamin B12 levels. Measure hematologic parameters annually and vitamin B12 at 2 to 3 year intervals and manage any abnormalities. (5.5)
  • Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. A lower dose of insulin or insulin secretagogue may be required. (5.6)
  • Hypersensitivity Reactions: There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with sitagliptin such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Promptly stop JANUMET, assess for other …
5.1 Lactic Acidosis

5.1 Lactic Acidosis There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension and resistant bradyarrhythmias have occurred with severe acidosis.

Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate/pyruvate ratio; metformin plasma levels were generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.

If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of JANUMET. In JANUMET-treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin HCl is dialyzable, with a clearance of up to 170 mL/min under good hemodynamic conditions).

Hemodialysis has often resulted in reversal of symptoms and recovery. Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue JANUMET and report these symptoms to their health care provider. For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below: Renal Impairment The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.

The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient's renal function include [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]: Before initiating JANUMET, obtain an estimated glomerular filtration rate (eGFR).

JANUMET is contraindicated in patients with an eGFR below 30 mL/min/1.73 m² [see Contraindications (4)]. JANUMET is not recommended in patients with an eGFR between 30 and less than 45 mL/min/1.73 m² because these patients require a lower dosage of sitagliptin than what is available in the fixed combination JANUMET product.

Obtain an eGFR at least annually in all patients taking JANUMET. In patients at increased risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently. Drug Interactions The concomitant use of JANUMET with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].

Therefore, consider more frequent monitoring of patients. Age 65 or Greater The risk of metformin-associated lactic acidosis increases with the patient's age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients [see Use in Specific Populations (8.5)].

Radiological Studies with Contrast Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop JANUMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.

Re-evaluate eGFR 48 hours after the imaging procedure, and restart JANUMET if renal function is stable. Surgery and Other Procedures Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension and renal impairment. JANUMET should be temporarily discontinued while patients have restricted food and fluid intake.

Hypoxic States Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia.

When such events occur, discontinue JANUMET. Excessive Alcohol Intake Alcohol potentiates the effect of metformin on lactate metabolism and this may increase the risk of metformin-associated lactic acidosis. Warn patients against excessive alcohol intake while receiving JANUMET. Hepatic Impairment Patients with hepatic impairment have developed with cases of metformin-associated lactic acidosis.

This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of JANUMET in patients with clinical or laboratory evidence of hepatic disease. Mitochondrial Diseases Metformin may increase the risk of lactic acidosis in patients with mitochondrial diseases such as mitochondrial encephalomyopathy with lactic acidosis, and stroke-like episodes (MELAS) syndrome and maternally inherited diabetes and deafness (MIDD).

JANUMET is not recommended in patients with mitochondrial diseases such as MELAS syndrome and MIDD. If a patient taking JANUMET develops elevated lactic acid levels (with or without accompanying neurologic signs and symptoms), discontinue JANUMET. Depending on the clinical context, consider evaluating the patient for MELAS, MIDD, or other mitochondrial disease.

5.2 Pancreatitis

5.2 Pancreatitis There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUMET. After initiation of JANUMET, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, JANUMET should promptly be discontinued and appropriate management should be initiated.

It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET.

5.3 Heart Failure

5.3 Heart Failure An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Consider the risks and benefits of JANUMET prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy.

Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JANUMET.

5.4 Acute Renal Failure

5.4 Acute Renal Failure There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. Before initiation of therapy with JANUMET and at least annually thereafter, renal function should be assessed. In patients in whom development of renal dysfunction is anticipated, particularly in elderly patients, renal function should be assessed more frequently and JANUMET discontinued if evidence of renal impairment is present.

JANUMET is contraindicated in patients with severe renal impairment [see Contraindications (4) and Warnings and Precautions (5.1)].

5.5 Vitamin B12 Deficiency

5.5 Vitamin B12 Deficiency In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12 -intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation.

Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels. Measure hematologic parameters on an annual basis and vitamin B12 measurements at 2- to 3-year intervals in patients on JANUMET and manage any abnormalities [see Adverse Reactions (6.1)].

5.6 Hypoglycemia with Concomitant Use with Insulin

5.6 Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues JANUMET may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue (e.g., sulfonylurea) [see Adverse Reactions (6)]. A lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with JANUMET [see Drug Interactions (7)].

5.7 Hypersensitivity Reactions

5.7 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions in patients treated with sitagliptin, one of the components of JANUMET. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with sitagliptin, with some reports occurring after the first dose.

If a hypersensitivity reaction is suspected, discontinue JANUMET, assess for other potential causes for the event, and institute alternative treatment for diabetes [see Adverse Reactions (6.2)]. Angioedema has also been reported with other DPP-4 inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUMET.

5.8 Severe and Disabling Arthralgia

5.8 Severe and Disabling Arthralgia There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication.

A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.

5.9 Bullous Pemphigoid

5.9 Bullous Pemphigoid Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving JANUMET.

If bullous pemphigoid is suspected, JANUMET should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.

Drug interactions

Drug or classSeverityEffectWhat to do
Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide)Adjust or monitorRaise lactic acidosis risk (label).Monitor more often.
Drugs that reduce metformin clearance (ranolazine, vandetanib, dolutegravir, cimetidine)Adjust or monitorHigher metformin exposure (label).Weigh benefit and risk; monitor.
Insulin or sulfonylureasAdjust or monitorMore hypoglycemia (label).Consider lower insulin or sulfonylurea dose.
Iodinated contrastAdjust or monitorContrast-induced kidney injury can precipitate lactic acidosis (label).Hold per label 2.3; recheck eGFR at 48 hours.
Alcohol (excess)Adjust or monitorPotentiates metformin effect on lactate (label).Advise against excess alcohol.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with JANUMET: Table 4: Clinically Significant Drug Interactions with JANUMET Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with JANUMET may increase the risk for lactic acidosis.

Intervention: Consider more frequent monitoring of these patients. Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide. Drugs that Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT 2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)].

Intervention: Consider the benefits and risks of concomitant use with JANUMET. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine. Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism. Intervention: Warn patients against alcohol intake while receiving JANUMET. Insulin Secretagogues or Insulin Clinical Impact: Coadministration of JANUMET with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia.

Intervention: Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin. Drugs Affecting Glycemic Control Clinical Impact: Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. Intervention: When such drugs are administered to a patient receiving JANUMET, observe the patient closely for loss of blood glucose control.

When such drugs are withdrawn from a patient receiving JANUMET, observe the patient closely for hypoglycemia. Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. Carbonic anhydrase inhibitors may increase risk of lactic acidosis.

Consider more frequent monitoring. (7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake.

(7)

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.

Sitagliptin is also a substrate of p-glycoprotein (P-gp), which may also be involved in mediating the renal elimination of sitagliptin.

However, cyclosporine, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin.

Sitagliptin In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4.

Sitagliptin is a P-gp substrate but does not inhibit P-gp mediated transport of digoxin.

In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraception (ethinyl estradiol and norethindrone) (Table 5), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT).

Drugs that Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT 2 ] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ].

Adverse reactions

Common

  • Diarrhea
  • Upper respiratory tract infection
  • Headache
  • Nausea, vomiting (metformin)

Serious

  • Lactic acidosis (boxed warning)
  • Pancreatitis
  • Hypersensitivity, angioedema, Stevens-Johnson syndrome
  • Bullous pemphigoid
  • Heart failure (DPP-4 inhibitor class warning)
  • Vitamin B12 deficiency
  • Severe arthralgia
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following adverse reactions are also discussed elsewhere in the labeling: Lactic Acidosis [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Heart Failure [see Warnings and Precautions (5.3)] Acute Renal Failure [see Warnings and Precautions (5.4)] Vitamin B12 Deficiency [see Warnings and Precautions (5.5)] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Severe and Disabling Arthralgia [see Warnings and Precautions (5.8)] Bullous Pemphigoid [see Warnings and Precautions (5.9)] The most common adverse reactions reported in ≥5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Sitagliptin and Metformin Coadministration in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise Table 1 summarizes the most common (≥5% of patients) adverse reactions reported (regardless of investigator assessment of causality) in a 24-week placebo-controlled factorial study in which sitagliptin and metformin were coadministered to patients with type 2 diabetes inadequately controlled on diet and exercise.

Table 1: Sitagliptin and Metformin Coadministered to Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Placebo) Intent-to-treat population. Number of Patients (%) Placebo Sitagliptin 100 mg once daily Metformin HCl 500 mg/ Metformin HCl 1000 mg twice daily Data pooled for the patients given the lower and higher doses of metformin.

Sitagliptin 50 mg twice daily + Metformin HCl 500 mg/ Metformin HCl 1000 mg twice daily N = 176 N = 179 N = 364 N = 372 Diarrhea 7 (4.0) 5 (2.8) 28 (7.7) 28 (7.5) Upper Respiratory Tract Infection 9 (5.1) 8 (4.5) 19 (5.2) 23 (6.2) Headache 5 (2.8) 2 (1.1) 14 (3.8) 22 (5.9) Sitagliptin Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone In a 24-week placebo-controlled trial of sitagliptin 100 mg administered once daily added to a twice daily metformin regimen, there were no adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients and more commonly than in patients given placebo. Discontinuation of therapy due to clinical adverse reactions was similar to the placebo treatment group (sitagliptin and metformin, 1.9%; placebo and metformin, 2.5%).

Gastrointestinal Adverse Reactions The incidences of pre-selected gastrointestinal adverse experiences in patients treated with sitagliptin and metformin were similar to those reported for patients treated with metformin alone. See Table 2. Table 2: Pre-selected Gastrointestinal Adverse Reactions (Regardless of Investigator Assessment of Causality) Reported in Patients with Type 2 Diabetes Receiving Sitagliptin and Metformin Number of Patients (%) Study of Sitagliptin and Metformin in Patients Inadequately Controlled on Diet and Exercise Study of Sitagliptin Add-on in Patients Inadequately Controlled on Metformin Alone Placebo Sitagliptin 100 mg once daily Metformin HCl 500 mg/ Metformin HCl 1000 mg twice daily Data pooled for the patients given the lower and higher doses of metformin.

Sitagliptin 50 mg twice daily + Metformin HCl 500 mg/ Metformin HCl 1000 mg twice daily Placebo and Metformin HCl ≥1500 mg daily Sitagliptin 100 mg once daily and Metformin HCl ≥1500 mg daily N = 176 N = 179 N = 364 N = 372 N = 237 N = 464 Diarrhea 7 (4.0) 5 (2.8) 28 (7.7) 28 (7.5) 6 (2.5) 11 (2.4) Nausea 2 (1.1) 2 (1.1) 20 (5.5) 18 (4.8) 2 (0.8) 6 (1.3) Vomiting 1 (0.6) 0 (0.0) 2 (0.5) 8 (2.2) 2 (0.8) 5 (1.1) Abdominal Pain Abdominal discomfort was included in the analysis of abdominal pain in the study of initial therapy. 4 (2.3) 6 (3.4) 14 (3.8) 11 (3.0) 9 (3.8) 10 (2.2) Sitagliptin in Combination with Metformin and Glimepiride In a 24-week placebo-controlled study of sitagliptin 100 mg as add-on therapy in patients with type 2 diabetes inadequately controlled on metformin and glimepiride (sitagliptin, N=116; placebo, N=113), the adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were: hypoglycemia (Table 3) and headache (6.9%, 2.7%). Sitagliptin in Combination with Metformin and Rosiglitazone In a placebo-controlled study of sitagliptin 100 mg as add-on therapy in patients with type 2 diabetes inadequately controlled on metformin and rosiglitazone (sitagliptin, N=181; placebo, N=97), the adverse reactions reported regardless of investigator assessment of causality through Week 18 in ≥5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were: upper respiratory tract infection (sitagliptin, 5.5%; placebo, 5.2%) and nasopharyngitis (6.1%, 4.1%).

Through Week 54, the adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were: upper respiratory tract infection (sitagliptin, 15.5%; placebo, 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache (5.5%, 4.1%). Sitagliptin in Combination with Metformin and Insulin In a 24-week placebo-controlled study of sitagliptin 100 mg as add-on therapy in patients with type 2 diabetes inadequately controlled on metformin and insulin (sitagliptin, N=229; placebo, N=233), the only adverse reaction reported regardless of investigator assessment of causality in ≥5% of patients treated with sitagliptin and more commonly than in patients treated with placebo was hypoglycemia (Table 3).

Hypoglycemia In the above studies (N=5), adverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required although most (77%) reports of hypoglycemia were accompanied by a blood glucose measurement ≤70 mg/dL. When the combination of sitagliptin and metformin was coadministered with a sulfonylurea or with insulin, the percentage of patients reporting at least one adverse reaction of hypoglycemia was higher than that observed with placebo and metformin coadministered with a sulfonylurea or with insulin (Table 3).

Table 3: Incidence and Rate of Hypoglycemia Adverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required: Intent-to-treat population. (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Clinical Studies of Sitagliptin in Combination with Metformin Coadministered with Glimepiride or Insulin Add-On to Glimepiride + Metformin (24 weeks) Sitagliptin 100 mg + Metformin + Glimepiride Placebo + Metformin + Glimepiride N = 116 N = 113 Overall (%) 19 (16.4) 1 (0.9) Rate (episodes/patient-year) Based on total number of events (i.e., a single patient may have had multiple events). 0.82 0.02 Severe (%) Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level/loss of consciousness or seizure. 0 (0.0) 0 (0.0) Add-On to Insulin + Metformin (24 weeks) Sitagliptin 100 mg + Metformin + Insulin Placebo + Metformin + Insulin N = 229 N = 233 Overall (%) 35 (15.3) 19 (8.2) Rate (episodes/patient-year) 0.98 0.61 Severe (%) 1 (0.4) 1 (0.4) The overall incidence of reported adverse reactions of hypoglycemia in patients with type 2 diabetes inadequately controlled on diet and exercise was 0.6% in patients given placebo, 0.6% in patients given sitagliptin alone, 0.8% in patients given metformin alone, and 1.6% in patients given sitagliptin in combination with metformin.

In patients with type 2 diabetes inadequately controlled on metformin alone, the overall incidence of adverse reactions of hypoglycemia was 1.3% in patients given add-on sitagliptin and 2.1% in patients given add-on placebo. In the study of sitagliptin and add-on combination therapy with metformin and rosiglitazone, the overall incidence of hypoglycemia was 2.2% in patients given add-on sitagliptin and 0.0% in patients given add-on placebo through Week 18.

Through Week 54, the overall incidence of hypoglycemia was 3.9% in patients given add-on sitagliptin and 1.0% in patients given add-on placebo. In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement ≤70 mg/dL) did not differ between the sitagliptin and placebo groups.

Vital Signs and Electrocardiograms With the combination of sitagliptin and metformin, no clinically meaningful changes in vital signs or in ECG (including in QTc interval) were observed. Pancreatitis In a pooled analysis of 19 double-blind clinical trials that included data from 10,246 patients randomized to receive sitagliptin 100 mg/day (N=5429) or corresponding (active or placebo) control (N=4817), the incidence of acute pancreatitis was 0.1 per 100 patient-years in each group (4 patients with an event in 4708 patient-years for sitagliptin and 4 patients with an event in 3942 patient-years for control).

Sitagliptin The most common adverse experience in sitagliptin monotherapy reported regardless of investigator assessment of causality in ≥5% of patients and more commonly than in patients given placebo was nasopharyngitis. Metformin The most common (>5%) established adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.

Laboratory Tests Sitagliptin The incidence of laboratory adverse reactions was similar in patients treated with sitagliptin and metformin (7.6%) compared to patients treated with placebo and metformin (8.7%). In most but not all studies, a small increase in white blood cell count (approximately 200 cells/microL difference in WBC vs. placebo; mean baseline WBC approximately 6600 cells/microL) was observed due to a small increase in neutrophils.

This change in laboratory parameters is not considered to be clinically relevant. Metformin In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12 -intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation.

6.2 Postmarketing Experience

6.2 Postmarketing Experience Additional adverse reactions have been identified during postapproval use of JANUMET, sitagliptin, or metformin. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions including Stevens-Johnson syndrome; upper respiratory tract infection; hepatic enzyme elevations; acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing pancreatitis [see Indications and Usage (1)]; worsening renal function, including acute renal failure (sometimes requiring dialysis) and tubulointerstitial nephritis; severe and disabling arthralgia; bullous pemphigoid; constipation; vomiting; headache; myalgia; pain in extremity; back pain; pruritus; mouth ulceration; stomatitis; cholestatic, hepatocellular, and mixed hepatocellular liver injury; rhabdomyolysis.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Sitagliptin and Metformin Coadministered to Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Placebo)Intent-to-treat population.
Number of Patients (%)
PlaceboSitagliptin 100 mg once dailyMetformin HCl 500 mg/ Metformin HCl 1000 mg twice dailyData pooled for the patients given the lower and higher doses of metformin.Sitagliptin 50 mg twice daily + Metformin HCl 500 mg/ Metformin HCl 1000 mg twice daily
N = 176N = 179N = 364N = 372
Diarrhea7 (4.0)5 (2.8)28 (7.7)28 (7.5)
Upper Respiratory Tract Infection9 (5.1)8 (4.5)19 (5.2)23 (6.2)
Headache5 (2.8)2 (1.1)14 (3.8)22 (5.9)
Table 2: Pre-selected Gastrointestinal Adverse Reactions (Regardless of Investigator Assessment of Causality) Reported in Patients with Type 2 Diabetes Receiving Sitagliptin and Metformin
Number of Patients (%)
Study of Sitagliptin and Metformin in Patients Inadequately Controlled on Diet and ExerciseStudy of Sitagliptin Add-on in Patients Inadequately Controlled on Metformin Alone
Placebo Sitagliptin 100 mg once daily Metformin HCl 500 mg/ Metformin HCl 1000 mg twice dailyData pooled for the patients given the lower and higher doses of metformin.Sitagliptin 50 mg twice daily + Metformin HCl 500 mg/ Metformin HCl 1000 mg twice dailyPlacebo and Metformin HCl ≥1500 mg dailySitagliptin 100 mg once daily and Metformin HCl ≥1500 mg daily
N = 176N = 179N = 364N = 372N = 237N = 464
Diarrhea7 (4.0)5 (2.8)28 (7.7)28 (7.5)6 (2.5)11 (2.4)
Nausea2 (1.1)2 (1.1)20 (5.5)18 (4.8)2 (0.8)6 (1.3)
Vomiting1 (0.6)0 (0.0)2 (0.5)8 (2.2)2 (0.8)5 (1.1)
Abdominal PainAbdominal discomfort was included in the analysis of abdominal pain in the study of initial therapy.4 (2.3)6 (3.4)14 (3.8)11 (3.0)9 (3.8)10 (2.2)
Table 3: Incidence and Rate of HypoglycemiaAdverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required: Intent-to-treat population. (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Clinical Studies of Sitagliptin in Combination with Metformin Coadministered with Glimepiride or Insulin
Add-On to Glimepiride + Metformin (24 weeks)Sitagliptin 100 mg + Metformin + GlimepiridePlacebo + Metformin + Glimepiride
N = 116 N = 113
Overall (%)19 (16.4)1 (0.9)
Rate (episodes/patient-year)Based on total number of events (i.e., a single patient may have had multiple events).0.820.02
Severe (%)Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level/loss of consciousness or seizure.0 (0.0)0 (0.0)
Add-On to Insulin + Metformin (24 weeks)Sitagliptin 100 mg + Metformin + InsulinPlacebo + Metformin + Insulin
N = 229N = 233
Overall (%)35 (15.3)19 (8.2)
Rate (episodes/patient-year)0.980.61
Severe (%)1 (0.4)1 (0.4)

Monitoring parameters

  • eGFR before starting and at least yearly; more often if eGFR <60 or at risk. Stop at or before iodinated contrast if eGFR 30–60, liver disease, alcoholism, heart failure or intra-arterial contrast; recheck eGFR at 48 hours (label 2.3). Hold during acute illness, dehydration or surgery. Vitamin B12 with long-term use. Hypoglycemia with insulin or sulfonylureas. Kidney
  • eGFR before starting and periodically
  • Hold for iodinated contrast per label
  • Vitamin B12 periodically
  • Glucose and hemoglobin A1c
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The limited available data with JANUMET in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see Data].

There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. No adverse developmental effects were observed when sitagliptin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 30-times and 20-times, respectively, the 100 mg clinical dose, based on AUC.

No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during organogenesis at doses up to 2- and 6-times, respectively, a 2000 mg clinical dose, based on body surface area [see Data]. The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a Hemoglobin A1c >7% and has been reported to be as high as 20-25% in women with a Hemoglobin A1c >10%.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications.

Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity. Data Human Data Published data from post-marketing studies do not report a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin is used during pregnancy.

However, these studies cannot definitely establish the absence of any risk because of methodological limitations, including small sample size and inconsistent comparator groups. Animal Data Sitagliptin and Metformin No animal reproduction studies were conducted with the coadministration of sitagliptin and metformin. Sitagliptin In embryo-fetal development studies, sitagliptin administered to pregnant rats and rabbits during organogenesis (gestation day 6 to 20) did not adversely affect developmental outcomes at oral doses up to 250 mg/kg (30-times the 100 mg clinical dose) and 125 mg/kg (20-times the 100 mg clinical dose), respectively, based on AUC.

Higher doses in rats associated with maternal toxicity increased the incidence of rib malformations in offspring at 1000 mg/kg, or approximately 100-times the clinical dose, based on AUC. Placental transfer of sitagliptin was observed in pregnant rats and rabbits. Sitagliptin administered to female rats from gestation day 6 to lactation day 21 caused no functional or behavioral toxicity in offspring of rats at doses up to 1000 mg/kg.

Metformin Metformin did not cause adverse developmental effects when administered to pregnant Sprague Dawley rats and rabbits up to 600 mg/kg/day during the period of organogenesis. This represents an exposure of about 2- and 6-times a 2000 mg clinical dose based on body surface area (mg/m 2) for rats and rabbits, respectively.

Mechanism of action

12.1 Mechanism of Action JANUMET JANUMET combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin HCl, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.

Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal.

These hormones are rapidly inactivated by the enzyme DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP.

GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses.

Metformin Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Sitagliptin In patients with type 2 diabetes mellitus, administration of sitagliptin led to inhibition of DPP-4 enzyme activity for a 24-hour period. After an oral glucose load or a meal, this DPP-4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased responsiveness of insulin release to glucose, resulting in higher C-peptide and insulin concentrations.

The rise in insulin with the decrease in glucagon was associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal. In studies with healthy subjects, sitagliptin did not lower blood glucose or cause hypoglycemia. Sitagliptin and Metformin Coadministration In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas metformin alone increased active and total GLP-1 concentrations to similar extents.

Coadministration of sitagliptin and metformin had an additive effect on active GLP-1 concentrations. Sitagliptin, but not metformin, increased active GIP concentrations. It is unclear what these findings mean for changes in glycemic control in patients with type 2 diabetes mellitus. Cardiac Electrophysiology In a randomized, placebo-controlled crossover study, 79 healthy subjects were administered a single oral dose of sitagliptin 100 mg, sitagliptin 800 mg (8 times the recommended dose), and placebo.

At the recommended dose of 100 mg, there was no effect on the QTc interval obtained at the peak plasma concentration, or at any other time during the study. Following the 800-mg dose, the maximum increase in the placebo-corrected mean change in QTc from baseline at 3 hours postdose was 8.0 msec. This increase is not considered to be clinically significant.

At the 800-mg dose, peak sitagliptin plasma concentrations were approximately 11 times higher than the peak concentrations following a 100-mg dose. In patients with type 2 diabetes mellitus administered sitagliptin 100 mg (N=81) or sitagliptin 200 mg (N=63) daily, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration.

Pharmacokinetics

Key PK parameters

Half-lifeSitagliptin about 12 hours; metformin about 6 hours (plasma)
Half-life in kidney failure (ESKD) kidneyBoth prolonged in kidney impairment
Protein bindingSitagliptin 38%; metformin negligible
Metabolism (CYP, transporters)Sitagliptin: minimal (CYP3A4, minor CYP2C8); metformin: not metabolized
Active metabolitesNone
Renal excretion kidneySitagliptin about 79% unchanged in urine; metformin about 90% unchanged in urine
Dialyzability kidneyMetformin yes; sitagliptin modest (13.5% per session; label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 µM∙hr, C max was 950 nM, and apparent terminal half-life (t 1/2 ) was 12.4 hours.

Elimination Sitagliptin Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination.

The apparent terminal t 1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min.

Metformin Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours.

In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Sitagliptin The pharmacokinetics of sitagliptin have been extensively characterized in healthy subjects and patients with type 2 diabetes mellitus. Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 µM∙hr, C max was 950 nM, and apparent terminal half-life (t 1/2) was 12.4 hours.

Plasma AUC of sitagliptin increased in a dose-proportional manner and increased approximately 14% following 100 mg doses at steady-state compared to the first dose. The intra-subject and inter-subject coefficients of variation for sitagliptin AUC were small (5.8% and 15.1%). The pharmacokinetics of sitagliptin was generally similar in healthy subjects and in patients with type 2 diabetes mellitus.

Absorption Sitagliptin After oral administration of a 100 mg dose to healthy subjects, sitagliptin was rapidly absorbed with peak plasma concentrations (median T max) occurring 1 to 4 hours postdose. The absolute bioavailability of sitagliptin is approximately 87%. Effect of Food Coadministration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics of sitagliptin.

Metformin The absolute bioavailability of a metformin HCl 500-mg tablet given under fasting conditions is approximately 50-60%. Studies using single oral doses of metformin HCl tablets 500 mg to 1,500 mg, and 850 mg to 2,550 mg (approximately 1.3 times the maximum recommended daily dosage), indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination.

Effect of Food Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C max), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T max) following administration of a single 850-mg tablet of metformin HCl with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.

Distribution Sitagliptin The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 liters. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%). Metformin The apparent volume of distribution (V/F) of metformin following single oral doses of metformin HCl tablets 850 mg averaged 654 ± 358 L.

Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin HCl tablets, steady-state plasma concentrations of metformin are reached within 24-48 hours and are generally <1 mcg/mL.

Elimination Sitagliptin Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. The apparent terminal t 1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Metformin Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours.

In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution. Metabolism Sitagliptin Following a [14 C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin.

In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8. Metformin Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.

Excretion Sitagliptin Following administration of an oral [14 C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion.

Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been established. Sitagliptin is also a substrate of p-glycoprotein (P-gp), which may also be involved in mediating the renal elimination of sitagliptin.

However, cyclosporine, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin. Metformin Elimination of metformin occurs primarily via renal excretion. Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination.

Specific Populations Patients with Renal Impairment JANUMET Studies characterizing the pharmacokinetics of sitagliptin and metformin after administration of JANUMET in renally impaired patients have not been performed [see Dosage and Administration (2.2)]. Sitagliptin An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to less than 45 mL/min/1.73 m², and an approximately 4-fold increase was observed in patients with severe renal impairment including patients with end-stage renal disease (ESRD) on hemodialysis, as compared to normal healthy control subjects [see Dosage and Administration (2.2)].

Metformin In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [see Contraindications (4) and Warnings and Precautions (5.1)]. Patients with Hepatic Impairment JANUMET Studies characterizing the pharmacokinetics of sitagliptin and metformin after administration of JANUMET in patients with hepatic impairment have not been performed.

Sitagliptin In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), mean AUC and C max of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sitagliptin. These differences are not considered to be clinically meaningful.

There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score >9) [see Use in Specific Populations (8.7)]. Metformin No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment. Effects of Age, Body Mass Index (BMI), Gender, and Race Sitagliptin Based on a population pharmacokinetic analysis or a composite analysis of available pharmacokinetic data, BMI, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of sitagliptin.

When the effects of age on renal function are taken into account, age alone did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.

Metformin Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C max is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.

Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes mellitus when analyzed according to gender. Similarly, in controlled clinical studies in patients with type 2 diabetes mellitus, the antihyperglycemic effect of metformin was comparable in males and females.

No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes mellitus, the antihyperglycemic effect was comparable in Whites (n=249), Blacks (n=51), and Hispanics (n=24). Drug Interaction Studies JANUMET Coadministration of multiple doses of sitagliptin (50 mg) and metformin HCl (1000 mg) given twice daily did not meaningfully alter the pharmacokinetics of either sitagliptin or metformin in patients with type 2 diabetes.

Pharmacokinetic drug interaction studies with JANUMET have not been performed; however, such studies have been conducted with the individual components of JANUMET (sitagliptin and metformin HCl). Sitagliptin In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4.

Sitagliptin is a P-gp substrate but does not inhibit P-gp mediated transport of digoxin. Based on these results, sitagliptin is considered unlikely to cause interactions with other drugs that utilize these pathways. Sitagliptin is not extensively bound to plasma proteins. Therefore, the propensity of sitagliptin to be involved in clinically meaningful drug-drug interactions mediated by plasma protein binding displacement is very low.

In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraception (ethinyl estradiol and norethindrone) (Table 5), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT). Table 5: Effect of Sitagliptin on Systemic Exposure of Coadministered Drugs Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified.

Dose of Sitagliptin Geometric Mean Ratio (ratio with/without sitagliptin) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified. C max Digoxin 0.25 mg Multiple dose. once daily for 10 days 100 mg once daily for 10 days Digoxin 1.11 AUC 0-24hr. 1.18 Glyburide 1.25 mg 200 mg once daily for 6 days Glyburide 1.09 1.01 Simvastatin 20 mg 200 mg once daily for 5 days Simvastatin 0.85 AUC 0-last. 0.80 Simvastatin Acid 1.12 1.06 Rosiglitazone 4 mg 200 mg once daily for 5 days Rosiglitazone 0.98 0.99 Warfarin 30 mg single dose on day 5 200 mg once daily for 11 days S(-) Warfarin 0.95 0.89 R(+) Warfarin 0.99 0.89 Ethinyl estradiol and norethindrone 21 days once daily of 35 µg ethinyl estradiol with norethindrone 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days 200 mg once daily for 21 days Ethinyl estradiol 0.99 0.97 Norethindrone 1.03 0.98 Metformin HCl 1000 mg twice daily for 14 days 50 mg twice daily for 7 days Metformin 1.02 AUC 0-12hr. 0.97 Effects of Other Drugs on Sitagliptin Clinical data described below suggest that sitagliptin is not susceptible to clinically meaningful interactions by coadministered medications (Table 6).

Table 6: Effect of Coadministered Drugs on Systemic Exposure of Sitagliptin Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified. Dose of Sitagliptin Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified.

C max Cyclosporine 600 mg once daily 100 mg once daily Sitagliptin 1.29 1.68 Metformin HCl 1000 mg Multiple dose. twice daily for 14 days 50 mg twice daily for 7 days Sitagliptin 1.02 AUC 0-12hr. 1.05 Metformin HCl Table 7: Effect of Metformin HCl on Systemic Exposure of Coadministered Drugs Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified. Dose of Metformin HCl Geometric Mean Ratio (ratio with/without metformin) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified.

C max Cimetidine 400 mg 850 mg Cimetidine 0.95 AUC 0-24hr. 1.01 Glyburide 5 mg 500 mg GLUMETZA (metformin HCl extended-release tablets) 500 mg. Glyburide 0.78 Ratio of arithmetic means, p value of difference <0.05. 0.63 Furosemide 40 mg 850 mg Furosemide 0.87 0.69 Nifedipine 10 mg 850 mg Nifedipine 1.10 1.08 Propranolol 40 mg 850 mg Propranolol 1.01 0.94 Ibuprofen 400 mg 850 mg Ibuprofen 0.97 Ratio of arithmetic means. 1.01 Table 8: Effect of Coadministered Drugs on Systemic Exposure of Metformin HCl Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified.

Dose of Metformin HCl Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified. C max Glyburide 5 mg 500 mg GLUMETZA (metformin HCl extended-release tablets) 500 mg. Metformin 0.98 Ratio of arithmetic means. 0.99 Furosemide 40 mg 850 mg Metformin 1.09 1.22 Nifedipine 10 mg 850 mg Metformin 1.16 1.21 Propranolol 40 mg 850 mg Metformin 0.90 0.94 Ibuprofen 400 mg 850 mg Metformin 1.05 1.07 Drugs that are eliminated by renal tubular secretion may increase the accumulation of metformin [see Warnings and Precautions (5.1) and Drug Interactions (7)].

Cimetidine 400 mg 850 mg Metformin 1.40 1.61 Carbonic anhydrase inhibitors may cause metabolic acidosis [see Warnings and Precautions (5.1) and Drug Interactions (7)]. Topiramate 100 mg Steady state 100 mg Topiramate every 12 hr + metformin HCl 500 mg every 12 hr AUC = AUC 0-12hr. 500 mg Metformin 1.25 1.17

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. JANUMET · Merck Sharp & Dohme LLC [US FDA-approved label, version 61, August 11, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d19c7ed0-ad5c-426e-b2df-722508f97d67
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Merck Sharp & Dohme LLC. (2026). JANUMET (sitagliptin and metformin HCl) tablets [Prescribing information; US FDA-approved label, NDA022044, set ID d19c7ed0-ad5c-426e-b2df-722508f97d67, version effective August 11, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d19c7ed0-ad5c-426e-b2df-722508f97d67
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1–S127. https://doi.org/10.1016/j.kint.2022.06.008
  5. de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090. https://doi.org/10.2337/dci22-0027

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .